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Abstract
Background: To determine the prognostic relevance of neuroendocrine differentiation in poorly differentiated
colorectal cancer.
Methods: The clinicopathological features and survival of 70 patients with poorly differentiated colorectal cancer were
analyzed retrospectively. Chromogranin A and synaptophysin were used as neuroendocrine markers. Patients
were followed-up for more than 3 years or until death.
Results: Of these 70 patients, 36 showed neuroendocrine differentiation. In univariate prognostic analysis, the
patients with lymph node metastasis (P < 0.001), advanced TNM stage (P < 0.001), and neuroendocrine differentiation
(P = 0.003) tended to have a poor prognosis. However, only lymph node metastasis was associated with a poor
prognosis in multivariate analysis (P < 0.001). Patients with neuroendocrine differentiation were associated with
lymph node metastasis (P = 0.006).
Conclusions: Neuroendocrine differentiation in poorly differentiated colorectal cancer was not a direct prognostic factor
in these patients. Lymph node metastasis was a direct prognostic factor in these patients. Patients with neuroendocrine
differentiation were associated with lymph node metastasis.
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Background
Neuroendocrine differentiation (NED) has been observed
in cancers of several non-neuroendocrine organs, includ-
ing the gastrointestinal tract. Many studies have evaluated
the clinical prognostic value of NED in colorectal cancer
(CRC). However, conflicting data exist in these studies. In
the study by Mori et al. [1], NED did not influence patient
prognosis. Similarly, Lloyd et al. [2] showed that, in 289
patients, NED did not influence prognosis in moderately
differentiated colorectal carcinomas. In contrast, in recent
years, studies have revealed that NED does influence
patient prognosis. Bernick et al. [3] studied 38 CRC
patients with NED and found that the prognosis of
these patients was poor. Similar findings were reported
in a meta-analysis by Zeng et al. [4]. Intriguingly, some
studies have indicated that CRC with NED was correlated
with liver metastasis and advanced tumor stages [3, 5].
Poorly differentiated colorectal cancer (PDCRC) com-
prises 5 to 25% of all CRCs [6–9]. It is known that PDCRC
is usually associated with a poor prognosis. NED is often
found in PDCRC [5]. The prognosis of PDCRC with NED
is currently still unclear. Here, we preliminarily studied




Between 2008 and 2012, 70 patients with primary
PDCRC who underwent radical resection were analyzed
retrospectively. All patients with TNM II and III tumors,
according to the 7th edition of the American Joint
Committee on Cancer/Union International control
Cancer (AJCC/UICC) tumor-node-metastasis (TNM)
staging system, received adjuvant therapy after surgery.
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Histology specimens were evaluated by two senior pathol-
ogists, and the diagnosis of PDCRC was confirmed in all
patients. Patients who died perioperatively and those with
distant organ metastasis or secondary malignancy were
excluded.
Immunohistochemistry
Hematoxylin and eosin-stained specimens from each
patient were available for review. In addition, each
specimen was analyzed for the biological markers of
NED, synaptophysin (Syn), and chromogranin A (CgA) by
immunohistochemistry. The number of Syn or CgA immu-
noreactive cells was determined using an eyepiece at high-
power field (HPF). Immunoreactive cells were counted
in at least ten most concentrated areas of tumor cells,
and the results were presented as the mean number of
immunoreactive cells per HPF. When no immunoreactive
tumor cells for CgA and Syn were noted in all tumor
fields, the tumor was classified as NED(−). Moreover,
when ≥1 tumor cells/HPF were positive for CgA and/or
Syn, the tumor was classified as NED(+) [10–12]. Further-
more, NED(+) tumors were assigned to three subgroups
based on the presence of immunoreactive cells per HPF:
subgroup 1(SG1) had less than 10% immunoreactive cells
of the total number of cells per HPF; subgroup 2(SG2)
had 10–20% immunoreactive cells; subgroup 3(SG3) had
more than 20% immunoreactive cells. According to the
2010 World Health Organization (WHO) classification,
specimens with more than 30% immunoreactive cells
were classified as mixed adenoneuroendocrine carcin-
oma (MANEC), and these patients were excluded from
the study.
Fig. 1 Prognostic analysis of clinicopathological factors for overall survival in PDCRC. a Kaplan-Meier survival analysis of N0 and N1 + N2 patients.
The patients with N stage(+) tended to have a poor prognosis (P < 0.001). b Kaplan-Meier survival analysis of TNM stage I, II, and III patients. The
patients with advanced TNM stage tended to have a poor prognosis (P < 0.001). c Kaplan-Meier survival analysis of NED(−) and NED(+) patients.
The patients with NED(+) tended to have a poor prognosis (P = 0.003)
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Statistics
All statistical analyses were performed using SPSS (version
16.0). Pearson’s chi-squared test was used to investigate
correlations of clinicopathological features between the
NED(+) and NED(−) groups. Multivariate analysis was
performed using logistic regression. Overall survival was
assessed by the Kaplan-Meier method. Statistical signifi-
cance between the survival curves of clinicopathological
features was calculated by the log rank test. Significant
variables were then examined by multivariate analysis




Seventy patients (36 males and 34 females) were diag-
nosed with PDCRC, including 36 (51.4%) NED(+) patients
and 34 (48.6%) NED(−) patients. The mean age was
60.2 years (range: 36–86 years). Of these patients, 2 had
stage I cancer, 17 had stage II, and 51 had stage III, which
included 45 cases of colon cancer and 25 cases of rectal
cancer. The median survival time of these patients was
47.656 months. Thirty-nine of 70 patients died during the
follow-up period.
Prognostic factors of PDCRC
Survival analyses were based on 70 patients with
complete follow-up data. Overall mean survival time was
47.656 months (95% confidence interval: 38.557–56.755)
and 3-year overall survival (3-year OS) was 0.469 ±
0.060.
In these PDCRC cases, the patients with N stage(+)
(P < 0.001), advanced TNM stage (P < 0.001), and NED(+)
(P = 0.003) tended to have a poor prognosis(Fig. 1). How-
ever, there was no significant difference in 3-year OS in
terms of age, gender, tumor location, lymph nodes
retrieved ,and T stage (Table 1).
In multivariate analysis using the Cox model, only
lymph node metastasis (LNM) was associated with a
poor prognosis (P < 0.001) (Table 1).
Moreover, by stratification analysis based on the degree
of NED, we analyzed the prognosis of SGs1, 2, and 3.
Interestingly, with the increasing presence of immunore-
active cells, the subgroup with higher expression tended
Table 1 Prognostic analysis of clinicopathological factors for overall survival in poor differentiated colorectal cancer patients
Clinicopathological factors Univariate analysis Multivariate analysis
Number(%) 3-year OS P value P value RR
Age 0.330
<65 years 43(61.4%) 0.510 ± 0.077
≥65 years 27(38.6%) 0.407 ± 0.095
Gender 0.582
Male 36(51.4%) 0.408 ± 0.083
Female 34(48.6%) 0.529 ± 0.086
Tumor location 0.092
Colon 45(64.3%) 0.503 ± 0.083
Rectum 25(35.7%) 0.315 ± 0.094
T stage 0.373
T1 + T2 5(7.1%) 0.600 ± 0.219
T3 + T4 65(92.9%) 0.459 ± 0.062
N stage <0.001* <0.001* 3.028
N0 19(27.1%) 0.895 ± 0.070
N1 + N2 51(72.9%) 0.310 ± 0.065
TNM stage <0.001* 0.384
I 2(2.9%) NAa
II 17(24.3%) 0.882 ± 0.078
III 51(72.8%) 0.310 ± 0.065
NED 0.003* 0.111
+ 36(51.4%) 0.272 ± 0.075
- 34(48.6%) 0.674 ± 0.081
*Indicated statistical significance (P < 0.05)
aNot applicable
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to have a poor prognosis. However, this trend did not
reach statistical significance (Fig. 2).
Clinicopathological features and neuroendocrine
differentiation
Univariate analysis revealed that N stage (P = 0.010)
and TNM stage (P = 0.018) had correlation with NED.
Furthermore, in multivariate analysis, only N stage was
associated with NED (P = 0.006). There was no signifi-
cant association between NED and age, gender, tumor
location, lymph nodes retrieved, and T stage (Table 2).
Discussion
In a previous study, the incidence of NED in PDCRC
was 41.5% [12]. In our study, the incidence was 51.4%,
which was close to that in Liu’s study. Since NED is
quite common in PDCRC, it is important to study the
influence of NED in PDCRC patients.
There is controversy regarding the prognostic signifi-
cance of NED in CRC [1–4, 13–15]. In our study, there
were statistically significant differences in 3-year OS in
terms of N stage, TNM stage, and NED in patients with
Table 2 Correlation between clinicopathological factors and neuroendocrine differentiation
Clinicopathological
factors
Number(%) NED Univariate analysis Multivariate analysis
+(SG1, SG2, SG3) – P value OR
Age 0.955
<65 years 43(61.4%) 22(15, 6, 1) 21
≥65 years 27(38.6%) 14(7, 6, 1) 13
Gender 0.816
Male 36(51.4%) 19(14, 4, 1) 17
Female 34(48.6%) 17(8, 8, 1) 17
Tumor location 0.943
Colon 45(64.3%) 23(13, 9, 1) 22
Rectum 25(35.7%) 13(9, 3, 1) 12
Lymph nodes retrieved 0.492
<12 18(25.7%) 8(6, 1, 1) 10
≥12 52(74.3%) 28(16, 11, 1) 24
T stage 0.669a
T1 + T2 5(7.1%) 2(2, 0, 0) 3
T3 + T4 65(92.9%) 34(20, 12, 2) 31
N stage 0.010* 0.006* 2.391
N0 19(27.1%) 5(5, 0, 0) 14
N1 + N2 51(72.9%) 31(17, 12, 2) 20
TNM stage 0.018b,* 0.755
I 2(2.9%) 0(0, 0, 0) 2
II 17(24.3%) 5(5, 0, 0) 12
III 51(72.8%) 31(17, 12, 2) 20
aFisher’s exact test
bLikelihood radio
*Indicated statistical significance (P < 0.05)
Fig. 2 Prognostic analysis of SGs 1, 2, and 3 for overall survival in
NED(+) patients. There were no significant differences among three
subgroups (P = 0.375)
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PDCRC. Multivariate analysis indicated that N stage(+)
was a significant negative prognostic factor for 3-year
OS, which was not surprising as this parameter is a well-
known marker with prognostic relevance [16–19]. In a
previous study, de Bruine et al. [14] suggested that
adenocarcinomas with NED tended to exhibit early
LNM, which was similar to the results in our correlation
analysis. We found that patients with NED were associ-
ated with LNM. Therefore, it may be deduced that NED,
which might influent LNM, affected the prognosis of
patients with PDCRC, rather than being a direct prog-
nostic factor in these patients. In many studies, there
were differences in the proportion of patients with LNM
due to small sample sizes [1–4, 13–15]. Therefore, this
may be the reason why there is controversy regarding
the prognostic significance of NED in CRC. Moreover,
the biological mechanisms underlying PDCRC with
NED and metastasis remain unclear. It is known that
neuroendocrine differentiated cells secrete neurohor-
monal substances by the autocrine or paracrine loop. In
a previous study, biogenic amines and polypeptide hor-
mones played a role in the growth regulation of normal
and neoplastic intestinal epithelia [20]. Hypothetically,
NED could stimulate growth and metastatic capacity
through the secretion of neurohormonal substances.
Moreover, by further stratified analysis, we found that
prognoses of three subgroups did not reach statistical
significance. But, the subgroup with higher expression
tended to have a poor prognosis. This might be due to
small sample size in our study. Therefore, further inves-
tigations are required to confirm this hypothesis.
TNM staging is a classic staging method used to predict
survival. However, with the development of molecular
medicine, TNM staging may be less reliable in predicting
survival, as shown in the research by Eschrich et al. They
argued that molecular staging might provide an accurate
prognosis for cancer patients [21]. Our data indicated that
patients with NED were associated with LNM. Therefore,
NED may be an important factor in molecular staging.
Several studies had indicated that the neuroendocrine
phenotype was associated with increased chemosensitivity
in lung cancer [22, 23] and in colorectal cell lines [24].
Therefore, NED might also be helpful in the therapy of
CRC. Further investigations are required in this area.
Conclusions
NED is a common event in PDCRC. NED in PDCRC is
not a direct prognostic factor in these patients. LNM is
a direct prognostic factor in these patients. Patients with
NED were associated with LNM. Moreover, NED, which
might influent LNM, affected the prognosis of patients
with PDCRC. Further research on this important issue is
required.
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